Global Pharmacovigilance Market to Reach $18.5 Billion by 2030
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.
New York, May 12, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pharmacovigilance Industry" - https://www.reportlinker.com/p06032498/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Pharmacovigilance Market to Reach $18.5 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Pharmacovigilance estimated at US$8.2 Billion in the year 2022, is projected to reach a revised size of US$18.5 Billion by 2030, growing at aCAGR of 10.6% over the period 2022-2030. Contract Outsourcing, one of the segments analyzed in the report, is projected to record 13.3% CAGR and reach US$12.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the In-House segment is readjusted to a revised 6.6% CAGR for the next 8-year period.
The U.S. Market is Estimated at $2.2 Billion, While China is Forecast to Grow at 15.3% CAGR
The Pharmacovigilance market in the U.S. is estimated at US$2.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2030 trailing a CAGR of 15.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.3% and 8.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.
Select Competitors (Total 32 Featured)
- Accenture
- ArisGlobal
- BioClinica Inc.
- Capgemini
- Cognizant
- FMD K&L
- IBM Corporation
- ICON Plc
- IQVIA
- ITClinical
- Laboratory Corporation of America Holdings
- Linical Accelovance
- Parexel International Corporation
- TAKE Solutions Ltd.
- United BioSource Corporation
- Wipro Ltd.
Read the full report: https://www.reportlinker.com/p06032498/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Pharmacovigilance - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Pharmacovigilance by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Pharmacovigilance by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Pharmacovigilance by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for
Contract Outsourcing by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Contract Outsourcing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 6: World 16-Year Perspective for Contract Outsourcing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
In-House by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for In-House by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 9: World 16-Year Perspective for In-House by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Cardiology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Cardiology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 12: World 16-Year Perspective for Cardiology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for
Respiratory Systems by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Respiratory Systems by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 15: World 16-Year Perspective for Respiratory Systems by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for
Other Therapeutic Areas by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Other Therapeutic Areas by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 18: World 16-Year Perspective for Other Therapeutic Areas
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for
Oncology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 21: World 16-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for
Neurology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 23: World Historic Review for Neurology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 24: World 16-Year Perspective for Neurology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 25: World Recent Past, Current & Future Analysis for
Pharma Companies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 26: World Historic Review for Pharma Companies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 27: World 16-Year Perspective for Pharma Companies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 28: World Recent Past, Current & Future Analysis for
Biotech Companies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 29: World Historic Review for Biotech Companies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 30: World 16-Year Perspective for Biotech Companies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 31: World Recent Past, Current & Future Analysis for
Medical Device Manufacturers by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 32: World Historic Review for Medical Device
Manufacturers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 33: World 16-Year Perspective for Medical Device
Manufacturers by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030
Table 34: World Recent Past, Current & Future Analysis for
Other End-Uses by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 35: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 36: World 16-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 37: World Recent Past, Current & Future Analysis for
Spontaneous Reporting by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 38: World Historic Review for Spontaneous Reporting by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 39: World 16-Year Perspective for Spontaneous Reporting
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 40: World Recent Past, Current & Future Analysis for
Intensified ADR Reporting by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 41: World Historic Review for Intensified ADR Reporting
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 42: World 16-Year Perspective for Intensified ADR
Reporting by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 43: World Recent Past, Current & Future Analysis for
Targeted Spontaneous Reporting by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 44: World Historic Review for Targeted Spontaneous
Reporting by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 45: World 16-Year Perspective for Targeted Spontaneous
Reporting by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 46: World Recent Past, Current & Future Analysis for
Cohort Event Monitoring by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 47: World Historic Review for Cohort Event Monitoring by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 48: World 16-Year Perspective for Cohort Event Monitoring
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 49: World Recent Past, Current & Future Analysis for EHR
Mining by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 50: World Historic Review for EHR Mining by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 51: World 16-Year Perspective for EHR Mining by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 52: World Pharmacovigilance Market Analysis of Annual
Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2023 (E)
Table 53: USA Recent Past, Current & Future Analysis for
Pharmacovigilance by Service Provider - Contract Outsourcing
and In-House - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 54: USA Historic Review for Pharmacovigilance by Service
Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 55: USA 16-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2014, 2023 &
2030
Table 56: USA Recent Past, Current & Future Analysis for
Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory
Systems, Other Therapeutic Areas, Oncology and Neurology -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 57: USA Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 58: USA 16-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2014, 2023 & 2030
Table 59: USA Recent Past, Current & Future Analysis for
Pharmacovigilance by End-Use - Pharma Companies, Biotech
Companies, Medical Device Manufacturers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 60: USA Historic Review for Pharmacovigilance by End-Use -
Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 61: USA 16-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2014, 2023 & 2030
Table 62: USA Recent Past, Current & Future Analysis for
Pharmacovigilance by Type - Spontaneous Reporting, Intensified
ADR Reporting, Targeted Spontaneous Reporting, Cohort Event
Monitoring and EHR Mining - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 63: USA Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 64: USA 16-Year Perspective for Pharmacovigilance by Type -
Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2014, 2023 & 2030
CANADA
Table 65: Canada Recent Past, Current & Future Analysis for
Pharmacovigilance by Service Provider - Contract Outsourcing
and In-House - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 66: Canada Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 67: Canada 16-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2014, 2023 &
2030
Table 68: Canada Recent Past, Current & Future Analysis for
Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory
Systems, Other Therapeutic Areas, Oncology and Neurology -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 69: Canada Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 70: Canada 16-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2014, 2023 & 2030
Table 71: Canada Recent Past, Current & Future Analysis for
Pharmacovigilance by End-Use - Pharma Companies, Biotech
Companies, Medical Device Manufacturers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 72: Canada Historic Review for Pharmacovigilance by
End-Use - Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 73: Canada 16-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2014, 2023 & 2030
Table 74: Canada Recent Past, Current & Future Analysis for
Pharmacovigilance by Type - Spontaneous Reporting, Intensified
ADR Reporting, Targeted Spontaneous Reporting, Cohort Event
Monitoring and EHR Mining - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 75: Canada Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 76: Canada 16-Year Perspective for Pharmacovigilance by
Type - Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2014, 2023 & 2030
JAPAN
Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2023 (E)
Table 77: Japan Recent Past, Current & Future Analysis for
Pharmacovigilance by Service Provider - Contract Outsourcing
and In-House - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 78: Japan Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 79: Japan 16-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2014, 2023 &
2030
Table 80: Japan Recent Past, Current & Future Analysis for
Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory
Systems, Other Therapeutic Areas, Oncology and Neurology -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 81: Japan Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 82: Japan 16-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2014, 2023 & 2030
Table 83: Japan Recent Past, Current & Future Analysis for
Pharmacovigilance by End-Use - Pharma Companies, Biotech
Companies, Medical Device Manufacturers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 84: Japan Historic Review for Pharmacovigilance by
End-Use - Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 85: Japan 16-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2014, 2023 & 2030
Table 86: Japan Recent Past, Current & Future Analysis for
Pharmacovigilance by Type - Spontaneous Reporting, Intensified
ADR Reporting, Targeted Spontaneous Reporting, Cohort Event
Monitoring and EHR Mining - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 87: Japan Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 88: Japan 16-Year Perspective for Pharmacovigilance by
Type - Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2014, 2023 & 2030
CHINA
Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2023 (E)
Table 89: China Recent Past, Current & Future Analysis for
Pharmacovigilance by Service Provider - Contract Outsourcing
and In-House - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 90: China Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 91: China 16-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2014, 2023 &
2030
Table 92: China Recent Past, Current & Future Analysis for
Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory
Systems, Other Therapeutic Areas, Oncology and Neurology -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 93: China Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 94: China 16-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2014, 2023 & 2030
Table 95: China Recent Past, Current & Future Analysis for
Pharmacovigilance by End-Use - Pharma Companies, Biotech
Companies, Medical Device Manufacturers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 96: China Historic Review for Pharmacovigilance by
End-Use - Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 97: China 16-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2014, 2023 & 2030
Table 98: China Recent Past, Current & Future Analysis for
Pharmacovigilance by Type - Spontaneous Reporting, Intensified
ADR Reporting, Targeted Spontaneous Reporting, Cohort Event
Monitoring and EHR Mining - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 99: China Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 100: China 16-Year Perspective for Pharmacovigilance by
Type - Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2014, 2023 & 2030
EUROPE
Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2023 (E)
Table 101: Europe Recent Past, Current & Future Analysis for
Pharmacovigilance by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 102: Europe Historic Review for Pharmacovigilance by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 103: Europe 16-Year Perspective for Pharmacovigilance by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030
Table 104: Europe Recent Past, Current & Future Analysis for
Pharmacovigilance by Service Provider - Contract Outsourcing
and In-House - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 105: Europe Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 106: Europe 16-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2014, 2023 &
2030
Table 107: Europe Recent Past, Current & Future Analysis for
Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory
Systems, Other Therapeutic Areas, Oncology and Neurology -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 108: Europe Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 109: Europe 16-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2014, 2023 & 2030
Table 110: Europe Recent Past, Current & Future Analysis for
Pharmacovigilance by End-Use - Pharma Companies, Biotech
Companies, Medical Device Manufacturers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 111: Europe Historic Review for Pharmacovigilance by
End-Use - Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 112: Europe 16-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2014, 2023 & 2030
Table 113: Europe Recent Past, Current & Future Analysis for
Pharmacovigilance by Type - Spontaneous Reporting, Intensified
ADR Reporting, Targeted Spontaneous Reporting, Cohort Event
Monitoring and EHR Mining - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 114: Europe Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 115: Europe 16-Year Perspective for Pharmacovigilance by
Type - Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2014, 2023 & 2030
FRANCE
Pharmacovigilance Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2023 (E)
Table 116: France Recent Past, Current & Future Analysis for
Pharmacovigilance by Service Provider - Contract Outsourcing
and In-House - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 117: France Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 118: France 16-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2014, 2023 &
2030
Table 119: France Recent Past, Current & Future Analysis for
Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory
Systems, Other Therapeutic Areas, Oncology and Neurology -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 120: France Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032498/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
